5.71
+0.12(+2.15%)
Currency In USD
| Previous Close | 5.59 |
| Open | 5.6 |
| Day High | 5.81 |
| Day Low | 5.58 |
| 52-Week High | 7.07 |
| 52-Week Low | 3.38 |
| Volume | 2.33M |
| Average Volume | 4.13M |
| Market Cap | 1.75B |
| PE | 57.1 |
| EPS | 0.1 |
| Moving Average 50 Days | 5.37 |
| Moving Average 200 Days | 4.74 |
| Change | 0.12 |
If you invested $1000 in MannKind Corporation (MNKD) 10 years ago, it would be worth $591.71 as of December 04, 2025 at a share price of $5.71. Whereas If you bought $1000 worth of MannKind Corporation (MNKD) shares 5 years ago, it would be worth $1,935.59 as of December 04, 2025 at a share price of $5.71.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
GlobeNewswire Inc.
Dec 01, 2025 1:05 PM GMT
If approved, ReadyFlow Autoinjector would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under 10 secondsWould potentially provide a cost-effective and convenient option to address episodes of fluid buildup at
MannKind to Present at the Jefferies Global Healthcare Conference
GlobeNewswire Inc.
Nov 11, 2025 9:05 PM GMT
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that Michael Castagna, Chief Executive Officer, and Chris Prentiss, Chief Financial Officer, are scheduled to present
MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease
GlobeNewswire Inc.
Nov 10, 2025 1:00 PM GMT
MannKind has made the decision to discontinue the ICoN-1 Phase 3 clinical trial evaluating nebulized clofazimine inhalation suspension for nontuberculous mycobacterial (NTM) lung disease, following a futility determination based on medical monitoring